Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

Effectiveness and safety of insulin glargine 300 U/mL in insulin-naïve patients with type 2 diabetes after failure of oral therapy in a real-world setting.

Pfohl M, Jornayvaz FR, Fritsche A, Pscherer S, Anderten H, Pegelow K, Seufert J.

Diabetes Obes Metab. 2020 Jan 5. doi: 10.1111/dom.13952. [Epub ahead of print]

PMID:
31903680
2.

HbA1c target achievement in the elderly: results of the Titration and Optimization trial for initiation of insulin glargine 100 U/mL in patients with type 2 diabetes poorly controlled on oral antidiabetic drugs.

Fritsche A, Anderten H, Pfohl M, Pscherer S, Borck A, Pegelow K, Bramlage P, Seufert J.

BMJ Open Diabetes Res Care. 2019 Aug 1;7(1):e000668. doi: 10.1136/bmjdrc-2019-000668. eCollection 2019.

3.

Titration of insulin glargine 100 U/mL when added to oral antidiabetic drugs in patients with type 2 diabetes: results of the TOP-1 real-world study.

Pscherer S, Anderten H, Pfohl M, Fritsche A, Borck A, Pegelow K, Bramlage P, Seufert J.

Acta Diabetol. 2020 Jan;57(1):89-99. doi: 10.1007/s00592-019-01383-w. Epub 2019 Jul 24.

PMID:
31342163
4.

Predictors of treatment response in type-2 diabetes patients initiating basal-supported oral therapy with insulin glargine 100 U/mL: A sub-analysis of the Titration and OPtimisation (TOP) registry.

Pfohl M, Pscherer S, Fritsche A, Anderten H, Borck A, Pegelow K, Bramlage P, Seufert J.

Diabetes Obes Metab. 2019 Sep;21(9):2169-2173. doi: 10.1111/dom.13768. Epub 2019 May 29.

PMID:
31069944
5.

Time to Insulin Initiation in Type 2 Diabetes Patients in 2010/2011 and 2016/2017 in Germany.

Kostev K, Gölz S, Scholz BM, Kaiser M, Pscherer S.

J Diabetes Sci Technol. 2019 Nov;13(6):1129-1134. doi: 10.1177/1932296819835196. Epub 2019 Mar 12.

6.

Titration and optimization trial for the initiation of insulin glargine 100 U/mL in patients with inadequately controlled type 2 diabetes on oral antidiabetic drugs.

Seufert J, Fritsche A, Pscherer S, Anderten H, Borck A, Pegelow K, Bramlage P, Pfohl M.

Diabetes Obes Metab. 2019 Feb;21(2):439-443. doi: 10.1111/dom.13535. Epub 2018 Oct 11.

PMID:
30226296
7.

Assessment of the Influence of Diabetes mellitus and Malnutrition on the Postoperative Complication Rate and Quality of Life of Patients in a Clinic Focused on Trauma Surgery.

Wintermeyer E, Ihle C, Ehnert S, Schreiner AJ, Stollhof L, Stöckle U, Nussler A, Fritsche A, Pscherer S.

Z Orthop Unfall. 2019 Apr;157(2):173-182. doi: 10.1055/a-0654-5504. Epub 2018 Jul 31. English, German.

PMID:
30064147
8.

Changes in Glycemic Control and Body Weight After Initiation of Dapagliflozin or Basal Insulin Supported Oral Therapy in Type 2 Diabetes: A Primary Care Database Study.

Kostev K, Pscherer S, Rist R, Busch S, Scheerer MF.

J Diabetes Sci Technol. 2017 May;11(3):590-596. doi: 10.1177/1932296816688011. Epub 2017 Jan 4.

9.

Delayed Fracture Healing in Diabetics with Distal Radius Fractures.

Pscherer S, Sandmann GH, Ehnert S, Nussler AK, Stöckle U, Freude T.

Acta Chir Orthop Traumatol Cech. 2017;84(1):24-29.

PMID:
28253942
10.

Development of a monoclonal sandwich ELISA for direct detection of bluetongue virus 8 in infected animals.

Ten Haaf A, Kohl J, Pscherer S, Hamann HP, Eskens HU, Bastian M, Gattenlöhner S, Tur MK.

J Virol Methods. 2017 May;243:172-176. doi: 10.1016/j.jviromet.2017.02.003. Epub 2017 Feb 11.

PMID:
28193493
11.

Distinct Gene Expression Patterns Defining Human Osteoblasts' Response to BMP2 Treatment: Is the Therapeutic Success All a Matter of Timing?

Ehnert S, Aspera-Werz RH, Freude T, Reumann MK, Ochs BG, Bahrs C, Schröter S, Wintermeyer E, Nussler AK, Pscherer S.

Eur Surg Res. 2016;57(3-4):197-210. Epub 2016 Jul 22.

PMID:
27441597
12.

[Retrospective Analysis of Diabetics with Regard to Treatment Duration and Costs].

Pscherer S, Nüssler A, Bahrs C, Reumann M, Ihle C, Stöckle U, Ehnert S, Freude T, Ochs BG, Flesch I, Ziegler P.

Z Orthop Unfall. 2017 Feb;155(1):72-76. doi: 10.1055/s-0042-116328. Epub 2016 Oct 21. German.

PMID:
27769089
13.

[Malnutrition in Elderly Trauma Patients - Comparison of Two Assessment Tools].

Ihle C, Bahrs C, Freude T, Bickel M, Spielhaupter I, Wintermeyer E, Stollhof L, Grünwald L, Ziegler P, Pscherer S, Stöckle U, Nussler A.

Z Orthop Unfall. 2017 Apr;155(2):184-193. doi: 10.1055/s-0042-116822. Epub 2016 Sep 29. German.

PMID:
27685613
14.

Titration of basal insulin or immediate addition of rapid acting insulin in patients not at target using basal insulin supported oral antidiabetic treatment - A prospective observational study in 2202 patients.

Siegmund T, Pfohl M, Forst T, Pscherer S, Bramlage P, Foersch J, Borck A, Seufert J.

Diabetes Metab Syndr. 2017 Jan - Mar;11(1):51-57. doi: 10.1016/j.dsx.2016.08.006. Epub 2016 Aug 24.

PMID:
27578616
15.

BMP9 a possible alternative drug for the recently withdrawn BMP7? New perspectives for (re-)implementation by personalized medicine.

Sreekumar V, Aspera-Werz RH, Tendulkar G, Reumann MK, Freude T, Breitkopf-Heinlein K, Dooley S, Pscherer S, Ochs BG, Flesch I, Hofmann V, Nussler AK, Ehnert S.

Arch Toxicol. 2017 Mar;91(3):1353-1366. doi: 10.1007/s00204-016-1796-6. Epub 2016 Jul 9.

PMID:
27394662
16.

Fracture risk in patients with type 2 diabetes under different antidiabetic treatment regimens: a retrospective database analysis in primary care.

Pscherer S, Kostev K, Dippel FW, Rathmann W.

Diabetes Metab Syndr Obes. 2016 Feb 19;9:17-23. doi: 10.2147/DMSO.S101370. eCollection 2016.

18.

Delayed Fracture Healing in Diabetics with Distal Radius Fractures.

Pscherer S, Sandmann GH, Ehnert S, Nussler AK, Stöckle U, Freude T.

Acta Chir Orthop Traumatol Cech. 2015;82(4):268-73.

PMID:
26516730
19.

Phage display-based on-slide selection of tumor-specific antibodies on formalin-fixed paraffin-embedded human tissue biopsies.

Ten Haaf A, Pscherer S, Fries K, Barth S, Gattenlöhner S, Tur MK.

Immunol Lett. 2015 Aug;166(2):65-78. doi: 10.1016/j.imlet.2015.05.013. Epub 2015 Jun 2.

PMID:
26045318
20.

Diabetes treatment in people with type 2 diabetes and schizophrenia: Retrospective primary care database analyses.

Rathmann W, Pscherer S, Konrad M, Kostev K.

Prim Care Diabetes. 2016 Feb;10(1):36-40. doi: 10.1016/j.pcd.2015.04.001. Epub 2015 Apr 27.

PMID:
25937183
21.

Treatment persistence after initiating basal insulin in type 2 diabetes patients: A primary care database analysis.

Pscherer S, Chou E, Dippel FW, Rathmann W, Kostev K.

Prim Care Diabetes. 2015 Oct;9(5):377-84. doi: 10.1016/j.pcd.2015.01.011. Epub 2015 Feb 18.

PMID:
25701545
22.

Factors circulating in the blood of type 2 diabetes mellitus patients affect osteoblast maturation - description of a novel in vitro model.

Ehnert S, Freude T, Ihle C, Mayer L, Braun B, Graeser J, Flesch I, Stöckle U, Nussler AK, Pscherer S.

Exp Cell Res. 2015 Mar 15;332(2):247-58. doi: 10.1016/j.yexcr.2014.12.011. Epub 2014 Dec 31.

PMID:
25557875
23.

Common Ewing sarcoma-associated antigens fail to induce natural T cell responses in both patients and healthy individuals.

Altvater B, Kailayangiri S, Theimann N, Ahlmann M, Farwick N, Chen C, Pscherer S, Neumann I, Mrachatz G, Hansmeier A, Hardes J, Gosheger G, Juergens H, Rossig C.

Cancer Immunol Immunother. 2014 Oct;63(10):1047-60. doi: 10.1007/s00262-014-1574-3. Epub 2014 Jun 28.

PMID:
24973179
24.

Increased oxidative stress response in granulocytes from older patients with a hip fracture may account for slow regeneration.

Wang Z, Ehnert S, Ihle C, Schyschka L, Pscherer S, Nussler NC, Braun KF, Van Griensven M, Wang G, Burgkart R, Stöckle U, Gebhard F, Vester H, Nussler AK.

Oxid Med Cell Longev. 2014;2014:819847. doi: 10.1155/2014/819847. Epub 2014 Mar 2.

25.

Gene expression changes in cancellous bone of type 2 diabetics: a biomolecular basis for diabetic bone disease.

Haug AT, Braun KF, Ehnert S, Mayer L, Stöckle U, Nüssler AK, Pscherer S, Freude T.

Langenbecks Arch Surg. 2014 Jun;399(5):639-47. doi: 10.1007/s00423-014-1188-4. Epub 2014 Apr 10.

PMID:
24715035
26.

Therapeutic peritoneal lavage with warm saline solution as an option for a critical hypothermic trauma patient.

Freude T, Gillen S, Ehnert S, Nüssler A, Stöckle U, Charalambakis N, Döbele S, Pscherer S.

Wien Klin Wochenschr. 2014 Jan;126(1-2):56-61. doi: 10.1007/s00508-013-0457-5. Epub 2013 Nov 19.

PMID:
24249326
27.

Composite efficacy parameters and predictors of hypoglycaemia in basal-plus insulin therapy--a combined analysis of 713 type 2 diabetic patients.

Seufert J, Brath H, Pscherer S, Borck A, Bramlage P, Siegmund T.

Diabetes Obes Metab. 2014 Mar;16(3):248-54. doi: 10.1111/dom.12211. Epub 2013 Sep 17.

PMID:
24033863
28.

Anti-diabetic treatment regulates pro-fibrotic TGF-β serum levels in type 2 diabetics.

Pscherer S, Freude T, Forst T, Nussler AK, Braun KF, Ehnert S.

Diabetol Metab Syndr. 2013 Aug 31;5(1):48. doi: 10.1186/1758-5996-5-48.

29.

Darbepoetin inhibits proliferation of hepatic cancer cells in the presence of TGF-β.

Ehnert S, Freude T, Eicher C, Burkhardt B, Martínez Sánchez JJ, Neumann J, Mühl-Benninghaus R, Dooley S, Pscherer S, Nussler AK.

Arch Toxicol. 2014 Jan;88(1):89-96. doi: 10.1007/s00204-013-1094-5. Epub 2013 Jul 23.

PMID:
23877120
30.

The right choice of antihypertensives protects primary human hepatocytes from ethanol- and recombinant human TGF-β1-induced cellular damage.

Ehnert S, Lukoschek T, Bachmann A, Martínez Sánchez JJ, Damm G, Nussler NC, Pscherer S, Stöckle U, Dooley S, Mueller S, Nussler AK.

Hepat Med. 2013 Mar 22;5:31-41. doi: 10.2147/HMER.S38754. eCollection 2013.

31.

Transforming growth factor β1 inhibits bone morphogenic protein (BMP)-2 and BMP-7 signaling via upregulation of Ski-related novel protein N (SnoN): possible mechanism for the failure of BMP therapy?

Ehnert S, Zhao J, Pscherer S, Freude T, Dooley S, Kolk A, Stöckle U, Nussler AK, Hube R.

BMC Med. 2012 Sep 7;10:101. doi: 10.1186/1741-7015-10-101.

32.

Hyperinsulinemia reduces osteoblast activity in vitro via upregulation of TGF-β.

Freude T, Braun KF, Haug A, Pscherer S, Stöckle U, Nussler AK, Ehnert S.

J Mol Med (Berl). 2012 Nov;90(11):1257-66. doi: 10.1007/s00109-012-0948-2. Epub 2012 Aug 29.

PMID:
22926010
33.

In type 2 diabetes patients, insulin glargine is associated with lower postprandial release of intact proinsulin compared with sulfonylurea treatment.

Pscherer S, Larbig M, von Stritsky B, Pfützner A, Forst T.

J Diabetes Sci Technol. 2012 May 1;6(3):634-40.

34.

Amputation rate and risk factors in type 2 patients with diabetic foot syndrome under real-life conditions in Germany.

Pscherer S, Dippel FW, Lauterbach S, Kostev K.

Prim Care Diabetes. 2012 Oct;6(3):241-6. doi: 10.1016/j.pcd.2012.02.004. Epub 2012 Mar 22.

PMID:
22445058
35.

The ganglioside antigen G(D2) is surface-expressed in Ewing sarcoma and allows for MHC-independent immune targeting.

Kailayangiri S, Altvater B, Meltzer J, Pscherer S, Luecke A, Dierkes C, Titze U, Leuchte K, Landmeier S, Hotfilder M, Dirksen U, Hardes J, Gosheger G, Juergens H, Rossig C.

Br J Cancer. 2012 Mar 13;106(6):1123-33. doi: 10.1038/bjc.2012.57. Epub 2012 Feb 28.

36.

Activated human γδ T cells induce peptide-specific CD8+ T-cell responses to tumor-associated self-antigens.

Altvater B, Pscherer S, Landmeier S, Kailayangiri S, Savoldo B, Juergens H, Rossig C.

Cancer Immunol Immunother. 2012 Mar;61(3):385-96. doi: 10.1007/s00262-011-1111-6. Epub 2011 Sep 18.

PMID:
21928126
37.

NK cells are dysfunctional in human chronic myelogenous leukemia before and on imatinib treatment and in BCR-ABL-positive mice.

Chen CI, Koschmieder S, Kerstiens L, Schemionek M, Altvater B, Pscherer S, Gerss J, Maecker HT, Berdel WE, Juergens H, Lee PP, Rossig C.

Leukemia. 2012 Mar;26(3):465-74. doi: 10.1038/leu.2011.239. Epub 2011 Sep 9.

PMID:
21904381
38.

Cost comparison of insulin glargine with insulin detemir in a basal-bolus regime with mealtime insulin aspart in type 2 diabetes in Germany.

Pscherer S, Dietrich ES, Dippel FW, Neilson AR.

Ger Med Sci. 2010 Aug 5;8. pii: Doc17. doi: 10.3205/000106.

39.

Effect of experimental hyperglycaemia on renal haemodynamics in prediabetic patients with and without AT1 receptor blockade.

Frank H, Pscherer S, Fliser D, Heemann U.

Eur J Clin Invest. 2010 May;40(5):414-21. doi: 10.1111/j.1365-2362.2010.02284.x.

PMID:
20534063
40.

Cytotoxic T cells transduced with chimeric anti-CD19 receptors prevent engraftment of primary lymphoblastic leukemia in vivo.

Landmeier S, Altvater B, Pscherer S, Meltzer J, Sebire N, Pule M, Vera J, Hotfilder M, Juergens H, Vormoor J, Rossig C.

Leukemia. 2010 May;24(5):1080-4. doi: 10.1038/leu.2010.38. Epub 2010 Mar 11. No abstract available.

PMID:
20220773
41.

Comparison of one-year costs of type 2 diabetes treatment with insulin glargine or insulin detemir in a basal supported oral therapy (BOT) in Germany.

Pscherer S, Dietrich ES, Dippel FW, Neilson AR.

Int J Clin Pharmacol Ther. 2010 Feb;48(2):129-37. Erratum in: Int J Clin Pharmacol Ther. 2010 Apr;48(4):296. Dosage error in article text.

PMID:
20137765
42.

Effect of Renin-Angiotensin system blockade on insulin resistance and inflammatory parameters in patients with impaired glucose tolerance.

Pscherer S, Heemann U, Frank H.

Diabetes Care. 2010 Apr;33(4):914-9. doi: 10.2337/dc09-1381. Epub 2010 Jan 19.

43.

2B4 (CD244) signaling by recombinant antigen-specific chimeric receptors costimulates natural killer cell activation to leukemia and neuroblastoma cells.

Altvater B, Landmeier S, Pscherer S, Temme J, Schweer K, Kailayangiri S, Campana D, Juergens H, Pule M, Rossig C.

Clin Cancer Res. 2009 Aug 1;15(15):4857-66. doi: 10.1158/1078-0432.CCR-08-2810. Epub 2009 Jul 28.

44.

A high proportion of bone marrow T cells with regulatory phenotype (CD4+CD25hiFoxP3+) in Ewing sarcoma patients is associated with metastatic disease.

Brinkrolf P, Landmeier S, Altvater B, Chen C, Pscherer S, Rosemann A, Ranft A, Dirksen U, Juergens H, Rossig C.

Int J Cancer. 2009 Aug 15;125(4):879-86. doi: 10.1002/ijc.24461.

45.

2B4 (CD244) signaling via chimeric receptors costimulates tumor-antigen specific proliferation and in vitro expansion of human T cells.

Altvater B, Landmeier S, Pscherer S, Temme J, Juergens H, Pule M, Rossig C.

Cancer Immunol Immunother. 2009 Dec;58(12):1991-2001. doi: 10.1007/s00262-009-0704-9. Epub 2009 Apr 10.

PMID:
19360406
46.

Activated human gammadelta T cells as stimulators of specific CD8+ T-cell responses to subdominant Epstein Barr virus epitopes: potential for immunotherapy of cancer.

Landmeier S, Altvater B, Pscherer S, Juergens H, Varnholt L, Hansmeier A, Bollard CM, Moosmann A, Bisping G, Rossig C.

J Immunother. 2009 Apr;32(3):310-21. doi: 10.1097/CJI.0b013e31819b7c30.

47.

Gene-engineered varicella-zoster virus reactive CD4+ cytotoxic T cells exert tumor-specific effector function.

Landmeier S, Altvater B, Pscherer S, Eing BR, Kuehn J, Rooney CM, Juergens H, Rossig C.

Cancer Res. 2007 Sep 1;67(17):8335-43.

48.

CD28 co-stimulation via tumour-specific chimaeric receptors induces an incomplete activation response in Epstein-Barr virus-specific effector memory T cells.

Altvater B, Pscherer S, Landmeier S, Niggemeier V, Juergens H, Vormoor J, Rossig C.

Clin Exp Immunol. 2006 Jun;144(3):447-57.

49.

Rhabdomyosarcoma lysis by T cells expressing a human autoantibody-based chimeric receptor targeting the fetal acetylcholine receptor.

Gattenlöhner S, Marx A, Markfort B, Pscherer S, Landmeier S, Juergens H, Müller-Hermelink HK, Matthews I, Beeson D, Vincent A, Rossig C.

Cancer Res. 2006 Jan 1;66(1):24-8.

50.

Target antigen expression on a professional antigen-presenting cell induces superior proliferative antitumor T-cell responses via chimeric T-cell receptors.

Rossig C, Bär A, Pscherer S, Altvater B, Pule M, Rooney CM, Brenner MK, Jürgens H, Vormoor J.

J Immunother. 2006 Jan-Feb;29(1):21-31.

PMID:
16365597

Supplemental Content

Loading ...
Support Center